Clinical trial
A trial of AK112 (PD1/VEGF bispecific) in combination with chemotherapy in patients with NSCLC
A trial of AK112 (PD1/VEGF bispecific) in combination with chemotherapy in patients with NSCLC
| Trial Fact Box | |
|---|---|
| NCT Code | NCT04736823 |
| Sponsor | Akeso |
| Study type(s) | Interventional |
| Phase | Phase 2 |
| Enrollment (Actual) | 265 |
| Study Start (Actual) | 01 February 2021 |
| Primary Completion (Estimated) | July 2026 |
| Study Completion (Estimated) | December 2026 |
Official Title:
A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
Brief Summary:
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
View full details